Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

Completed · Phase 2

Conditions studied: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis

In brief

To assess the safety of treatment with pirfenidone (up to 3600 mg/d) in patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF).

Key facts

Study ID

NCT00080223

Run by

Genentech, Inc.

People needed

83

Starts

2003-08-31

Expected to finish

2015-04-30

Last updated by the study team

2017-04-17

Who can join

Age: 40 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Pomona, California, United States
• Study site — San Jose, California, United States
• Study site — New Haven, Connecticut, United States
• Study site — Sarasota, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Kailua, Hawaii, United States
• Study site — Lahaina, Hawaii, United States
• Study site — Nampa, Idaho, United States
• Study site — Elk Grove Village, Illinois, United States
• Study site — Boston, Massachusetts, United States
• Study site — West Roxbury, Massachusetts, United States
• Study site — St Louis, Missouri, United States
• Study site — Huntington Station, New York, United States
• Study site — New York, New York, United States
• Study site — New York, New York, United States
• Study site — Rochester, New York, United States
• Study site — Worthington, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Portland, Oregon, United States
• Study site — Lancaster, Pennsylvania, United States
• Study site — Dallas, Texas, United States
• Study site — Houston, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Provo, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.